The Clinical Measures Associated with C-peptide Decline in Patients with Type 1 Diabetes over 15 Years

被引:15
作者
Lee, Tae Ho [1 ]
Kwon, Ah Reum [1 ]
Kim, Ye Jin [1 ]
Chae, Hyun Wook [1 ]
Kim, Ho Seong [1 ]
Kim, Duk Hee [2 ]
机构
[1] Yonsei Univ, Coll Med, Dept Pediat, Seoul, South Korea
[2] Sowha Childrens Hosp, Seoul, South Korea
关键词
Diabetes Mellitus; Type; 1; C-Peptide; Body Weight; Body Mass Index; Diabetic Ketoacidosis; BETA-CELL FUNCTION; INSULIN-RESISTANCE; NATURAL-HISTORY; GLUCOSE; HYPERGLYCEMIA; PROGRESSION; SECRETION; THERAPY;
D O I
10.3346/jkms.2013.28.9.1340
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study was done to characterize the natural course of C-peptide levels in patients with type 1 diabetes and identify distinguishing characters among patients with lower rates of C-peptide decline. A sample of 95 children with type 1 diabetes was analyzed to retrospectively track serum levels of C-peptide, HbA1c, weight, BMI, and diabetic complications for the 15 yr after diagnosis. The clinical characteristics were compared between the patients with low and high C-peptide levels, respectively. The average C-peptide level among all patients was significantly reduced five years after diagnosis (P < 0.001). The incidence of diabetic ketoacidosis was significantly lower among the patients with high levels of C-peptide (P = 0.038). The body weight and BMI standard deviation scores (SDS) 15 yr after diagnosis were significantly higher among the patients with low C-peptide levels (weight SDS, P = 0.012; BMI SDS, P = 0.044). In conclusion, C-peptide level was significantly decreased after 5 yr from diagnosis. Type 1 diabetes patients whose beta-cell functions were preserved might have low incidence of diabetic ketoacidosis. The declines of C-peptide level after diagnosis in type 1 diabetes may be associated with changes of body weight and BMI.
引用
收藏
页码:1340 / 1344
页数:5
相关论文
共 31 条
[1]   Natural history of type 1 diabetes [J].
Achenbach, P ;
Bonifacio, E ;
Koczwara, K ;
Ziegler, AG .
DIABETES, 2005, 54 :S25-S31
[2]  
[Anonymous], 1995, DIABETES, V44, P968
[3]   INTENSIVE INSULIN THERAPY AND WEIGHT-GAIN IN IDDM [J].
CARLSON, MG ;
CAMPBELL, PJ .
DIABETES, 1993, 42 (12) :1700-1707
[4]  
DCCT Res Grp, 1988, DIABETES CARE, V11, P567
[5]   INSULIN RESISTANCE - A MULTIFACETED SYNDROME RESPONSIBLE FOR NIDDM, OBESITY, HYPERTENSION, DYSLIPIDEMIA, AND ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE [J].
DEFRONZO, RA ;
FERRANNINI, E .
DIABETES CARE, 1991, 14 (03) :173-194
[7]   PROLONGED EXPOSURE OF HUMAN PANCREATIC-ISLETS TO HIGH GLUCOSE-CONCENTRATIONS INVITRO IMPAIRS THE BETA-CELL FUNCTION [J].
EIZIRIK, DL ;
KORBUTT, GS ;
HELLERSTROM, C .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (04) :1263-1268
[8]   C-peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy [J].
Ekberg, Karin ;
Brismar, Tom ;
Johansson, Bo-Lennart ;
Lindstrom, Per ;
Juntti-Berggren, Lisa ;
Norbhy, Anders ;
Berne, Christian ;
Arnqvist, Hans J. ;
Bolinder, Jan ;
Wahren, John .
DIABETES CARE, 2007, 30 (01) :71-76
[9]   Insulin resistance in type 1 diabetes [J].
Greenbaum, CJ .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2002, 18 (03) :192-200
[10]   Relationship of β-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes -: Follow-up of the Seattle Family Study [J].
Greenbaum, CJ ;
Sears, KL ;
Kahn, SE ;
Palmer, JP .
DIABETES, 1999, 48 (01) :170-175